Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151089 | 0.90 | LPL (0.52) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5243207 | 0.85 | CA1 (0.61) | CA1CA2CA9LPLLIPG | |
| SCHEMBL805968 | 0.83 | CA1 (0.49) | CA1CA2CA9LPLLIPG | |
| SCHEMBL14754517 | 0.80 | CA1 (0.53) | CA1CA2CA9LPLLIPG | |
| SCHEMBL5899727 | 0.78 | LPL (0.65) | CA1CA2CA9LPLLIPG | |
| SCHEMBL623833 | 0.78 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL25658494 | 0.78 | CA1 (0.54) | CA1CA2CA9LPLLIPG | |
| SCHEMBL20639612 | 0.78 | LPL (0.41) | CA1CA2CA9LPLLIPG | |
| SCHEMBL547582 | 0.77 | RAB9A (0.52) | — | |
| SCHEMBL17423566 | 0.77 | CA1 (0.53) | CA1CA2CA9LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748621-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ADDEX PHARMA, S.A. (CH) | 2012-12-06 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252937-B2 | 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones | Janssen Pharmaceuticals, Inc. (US) | 2012-08-28 | — | — | US | disclosed |
| EP-2200985-B1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO MCNEIL JANSSEN PHARM (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2200985-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009033702-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309793-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | CA1 4254/4885CA2 1717/4885CA9 4847/4885 |
| US-20100286206-A1 | 1,3-DISUBSTITUTED 4-(ARYL-X-PHENYL)-1H-PYRIDIN-2-ONES | GRM2, GRM1, GRM3 | CA1 4254/4885CA2 1717/4885CA9 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.